Trial Profile
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Amfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Tris Pharma
- 01 Feb 2023 Results of post hoc analysis assessing the overall effect size as well as the effect size at each time point from early morning through evening (1, 2, 4, 6, 8, 10, 12, and 13 hours postdose for each efficacy measure, published in the Journal of Child and Adolescent Psychopharmacology
- 12 Nov 2018 Results presented in the Tris Pharma media release.
- 12 Nov 2018 According to a Tris Pharma media release, data from this trial was presented at the 2018 Neuroscience Education Institute (NEI) Congress.